Ann: Immutep Investor Update, page-3

EAT COVID data expected *by* end of year;

A few notes:

*By* end of year, means anytime till then,

The length of time is necessary to demonstrate (as required) efficacy, even if there is no short term complications are observed and that brings me to the next point;

This is a case of "No news is good news", the longer the better as it will imply better efficacy! And that leads to the next point,

At least to people who look beyond Covid, with a long term view of use of efti, this trial has a much more far reaching consequent benefit for IMM if successful, well out-weighing financial gain during covid (there are a lot of vaccines, and other supplementary drugs out there already). Good results will take us a level beyond even the current hope of what efti can do and that whether or not covid will be here or not is irrelevant. As unfortunate as it has been, Covid was otherwise best opportunity to see what Lag-3 does there.

Finally, imagine by end of the year we have application of efti with diseaseS (yes with plural) such as covid AND IMP761 in auto-immune proving worthy of clinical trial ...

... We will have A LOT OF ground covered by next year unlike other companies whose focus or drug application are limited to oncology or just a few types of cancer.